Alaunos net loss narrows to $1.9 million in Q2 2026; revenue posts no revenue in H1 2026

PUBT · 1d ago
Alaunos net loss narrows to $1.9 million in Q2 2026; revenue posts no revenue in H1 2026
  • Alaunos posted a net loss of $1.9 million for the six months ended June 30, 2026, with no royalty revenue.
  • R&D expense climbed 53% to $814,000, driven by higher stock-based compensation, salaries, consulting tied to its obesity program.
  • G&A expense fell 28% to $1.15 million on lower salaries, insurance, filing, banking, legal, travel costs following downsized operations.
  • Cash and equivalents totaled $120,000 at June 30, 2026; monthly cash burn runs about $210,000, funding expected into Q3 2026.
  • Lead preclinical candidate ALN1003 advanced on DIO mouse data; Nasdaq flagged a stockholders’ equity shortfall versus the $2.5 million requirement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alaunos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-352421), on August 14, 2026, and is solely responsible for the information contained therein.